72 results
8-K
EX-99.1
CDXC
Chromadex Corp
8 Nov 23
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
4:02pm
serve as a testament to our commitment to financial discipline and operational efficiency. ChromaDex is in its strongest financial position to date
8-K
EX-99.2
CDXC
Chromadex Corp
8 Nov 23
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
4:02pm
in business mix. Sales and Marketing % of Net Sales 6,035 31.0% 5,868 34.4% Improvements reflect an ongoing commitment to optimizing marketing
8-K
EX-99.1
CDXC
Chromadex Corp
9 Aug 23
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
4:02pm
our commitment to consistent profitable growth.”
(1) Refers to two independent clinical study abstracts originally presented in April 2023
8-K
EX-99.2
z130c8gw7gplefw95
9 Aug 23
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-10.1
hk59c
20 Jun 23
Departure of Directors or Certain Officers
4:00pm
8-K
EX-99.2
y0p1 jfgcqylw6
2 Nov 22
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
4:02pm
8-K
EX-99.1
iwxhb
2 Nov 22
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
4:02pm
8-K
hm8gaie
11 Oct 22
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
4:05pm
8-K
EX-99.1
v897qm0mxljd62l5m
11 Oct 22
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
4:05pm
8-K
EX-10.2
lsa4q8hi5dh
3 Oct 22
Entry into a Material Definitive Agreement
6:43am
8-K
EX-10.1
oqye nhgfc
3 Oct 22
Entry into a Material Definitive Agreement
6:43am
8-K
EX-10.1
iogod
10 Aug 22
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-10.2
qburj
10 Aug 22
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
4:06pm